Published in Psychopharmacology (Berl) on December 24, 2011
Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior. Am J Psychiatry (2014) 1.54
Selective Serotonin Reuptake Inhibitors and Violent Crime: A Cohort Study. PLoS Med (2015) 1.54
Effects of chronic fluoxetine treatment on neurogenesis and tryptophan hydroxylase expression in adolescent and adult rats. PLoS One (2014) 1.49
Behavioral and neurogenomic transcriptome changes in wild-derived zebrafish with fluoxetine treatment. BMC Genomics (2013) 0.90
The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and design. BMC Psychiatry (2014) 0.79
Cocaine-conditioned odor cues without chronic exposure: Implications for the development of addiction vulnerability. Neuroimage Clin (2015) 0.75
Increased response to a 5-HT challenge after discontinuation of chronic serotonin uptake inhibition in the adult and adolescent rat brain. PLoS One (2014) 0.75
Recent Advances in Translational Magnetic Resonance Imaging in Animal Models of Stress and Depression. Front Cell Neurosci (2017) 0.75
The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev (2000) 17.59
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods (1985) 9.05
Depression: a new animal model sensitive to antidepressant treatments. Nature (1977) 8.76
Allelic variation of human serotonin transporter gene expression. J Neurochem (1996) 7.08
Long story short: the serotonin transporter in emotion regulation and social cognition. Nat Neurosci (2007) 3.66
Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study. Arch Gen Psychiatry (2006) 1.93
The human serotonin transporter gene polymorphism--basic research and clinical implications. J Neural Transm (Vienna) (1997) 1.39
Serotonin as a developmental signal. Behav Brain Res (1996) 1.37
Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci (1999) 1.32
Antidepressant drug-induced stimulation of mouse hippocampal neurogenesis is age-dependent and altered by early life stress. J Comp Neurol (2008) 1.30
Ageing abolishes the effects of fluoxetine on neurogenesis. Mol Psychiatry (2009) 1.28
Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood. Brain Res Dev Brain Res (2000) 1.26
'It's not over when it's over': persistent neurobiological abnormalities in recovered depressed patients. Psychol Med (2008) 1.23
Up-regulation of tryptophan hydroxylase-2 mRNA in the rat brain by chronic fluoxetine treatment correlates with its antidepressant effect. Neuroscience (2007) 1.17
Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf (2006) 1.15
Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl) (2005) 1.14
In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI. Neuroimage (2006) 1.10
The effects of intra-uterine growth retardation and postnatal undernutrition on onset of puberty in male and female rats. Pediatr Res (2000) 1.06
Altering the course of neurodevelopment: a framework for understanding the enduring effects of psychotropic drugs. Int J Dev Neurosci (2004) 1.04
Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl) (1990) 1.03
Role of the amygdala in antidepressant effects on hippocampal cell proliferation and survival and on depression-like behavior in the rat. PLoS One (2010) 1.02
Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS One (2011) 1.01
Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse (2001) 1.00
Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci (1994) 0.99
Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Brain Res Mol Brain Res (1993) 0.98
Short- and long-term functional consequences of fluoxetine exposure during adolescence in male rats. Biol Psychiatry (2010) 0.98
Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther (2000) 0.89
Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats. Physiol Behav (1999) 0.85
Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. J Child Adolesc Psychopharmacol (1999) 0.85
Stimulation of astroglial serotonin receptors produces culture media which regulates growth of serotonergic neurons. Brain Res (1989) 0.85
Bare-bones fact--children are not small adults. N Engl J Med (2004) 0.84
Depression in children. Curr Opin Psychiatry (2008) 0.83
Evidence that increased 5-HT release evokes region-specific effects on blood-oxygenation level-dependent functional magnetic resonance imaging responses in the rat brain. Neuroscience (2009) 0.83
Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors. Eur J Pharmacol (2002) 0.83
Effects of fluoxetine and norfluoxetine on 5-hydroxytryptamine metabolism in blood platelets and brain after administration to rats. J Pharm Pharmacol (1998) 0.81
Comparative in vivo study of iodine-123-labeled beta-CIT and nor-beta-CIT binding to serotonin transporters in rat brain. Synapse (1999) 0.79
Adolescent fluoxetine exposure produces enduring, sex-specific alterations of visual discrimination and attention in rats. Neurotoxicol Teratol (2006) 0.79
Sex-dependent effects of fluoxetine and triiodothyronine in the forced swim test in rats. Eur Neuropsychopharmacol (2005) 0.78
Predicting sensorimotor and memory deficits after neonatal ischemic stroke with reperfusion in the rat. Behav Brain Res (2010) 0.77
Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol (2004) 3.79
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25
Liver fat content and T2*: simultaneous measurement by using breath-hold multiecho MR imaging at 3.0 T--feasibility. Radiology (2008) 2.25
Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 2.23
EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging (2010) 2.09
The adhesive removal test: a sensitive method to assess sensorimotor deficits in mice. Nat Protoc (2009) 1.87
Sensorimotor and cognitive deficits after transient middle cerebral artery occlusion in the mouse. Exp Neurol (2006) 1.86
Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp (2010) 1.83
Differences in the evolution of the ischemic penumbra in stroke-prone spontaneously hypertensive and Wistar-Kyoto rats. Stroke (2009) 1.71
Effects of perinatal exposure to waterborne fluoxetine on memory processing in the cuttlefish Sepia officinalis. Aquat Toxicol (2013) 1.68
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging (2009) 1.49
Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry (2012) 1.47
Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging (2012) 1.47
EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging (2009) 1.45
Cerebral impairment in chronic solvent-induced encephalopathy. Ann Neurol (2008) 1.45
Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp (2011) 1.40
Potential use of oxygen as a metabolic biosensor in combination with T2*-weighted MRI to define the ischemic penumbra. J Cereb Blood Flow Metab (2008) 1.35
Post-stroke depression: mechanisms, translation and therapy. J Cell Mol Med (2012) 1.34
Behavioral deficits after distal focal cerebral ischemia in mice: Usefulness of adhesive removal test. Behav Neurosci (2009) 1.33
White matter fractional anisotropy correlates with speed of processing and motor speed in young childhood cancer survivors. Int J Radiat Oncol Biol Phys (2008) 1.30
Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects. EJNMMI Res (2011) 1.29
SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med (2011) 1.28
Anaesthesia and physiological monitoring during in vivo imaging of laboratory rodents: considerations on experimental outcomes and animal welfare. EJNMMI Res (2012) 1.25
Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med (2008) 1.23
European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging (2012) 1.19
Molecular SPECT Imaging: An Overview. Int J Mol Imaging (2011) 1.18
Object recognition test in mice. Nat Protoc (2013) 1.17
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord (2009) 1.15
Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry (2004) 1.15
Neurobiological substrates of cue-elicited craving and anhedonia in recently abstinent opioid-dependent males. Drug Alcohol Depend (2008) 1.14
Differential effects of NMDA and AMPA glutamate receptors on functional magnetic resonance imaging signals and evoked neuronal activity during forepaw stimulation of the rat. J Neurosci (2006) 1.11
Long-term functional outcome following transient middle cerebral artery occlusion in the rat: correlation between brain damage and behavioral impairment. Behav Neurosci (2006) 1.10
Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry (2009) 1.09
Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat. Eur J Neurosci (2006) 1.08
Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain (2008) 1.08
In vivo fluorescence lifetime tomography of a FRET probe expressed in mouse. Biomed Opt Express (2011) 1.07
Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. Eur Neuropsychopharmacol (2008) 1.06
New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization. J Med Chem (2003) 1.06
Sepiapterin reductase deficiency an autosomal recessive DOPA-responsive dystonia. Mol Genet Metab (2006) 1.03
The acute and chronic effects of MDMA ("ecstasy") on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology (2002) 1.03
Combined therapeutic strategy using erythropoietin and mesenchymal stem cells potentiates neurogenesis after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab (2008) 1.03
Cerebral blood flow changes during script-driven imagery in police officers with posttraumatic stress disorder. Biol Psychiatry (2004) 1.02
Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS One (2011) 1.01
Identification of an essential endogenous regulator of blood-brain barrier integrity, and its pathological and therapeutic implications. Proc Natl Acad Sci U S A (2012) 1.01
Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J Neurol Neurosurg Psychiatry (2009) 0.99
Delayed hypoxic postconditioning protects against cerebral ischemia in the mouse. Stroke (2009) 0.99
Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology (2008) 0.98
Value of semiquantitative analysis for clinical reporting of 123I-2-β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane SPECT studies. J Nucl Med (2013) 0.98
Somatostatin receptor scintigraphy in nasopharyngeal carcinoma. Clin Nucl Med (2008) 0.97
Co-occurrence of early-onset Parkinson disease and 22q11.2 deletion syndrome: Potential role for dopamine transporter imaging. Am J Med Genet A (2010) 0.97
A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users. Neuropsychopharmacology (2006) 0.96
On the importance of long-term functional assessment after stroke to improve translation from bench to bedside. Exp Transl Stroke Med (2011) 0.96
The role of dopamine in human addiction: from reward to motivated attention. Eur J Pharmacol (2005) 0.96
Imaging technologies for preclinical models of bone and joint disorders. EJNMMI Res (2011) 0.94
Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging (2012) 0.93
Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur J Nucl Med Mol Imaging (2009) 0.93
Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory. J Cell Sci (2007) 0.93
Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl) (2004) 0.93
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry (2003) 0.93
Estrogen receptor beta agonist diarylpropiolnitrile (DPN) does not mediate neuroprotection in a rat model of permanent focal ischemia. Brain Res (2007) 0.92
Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J Psychopharmacol (2006) 0.92
Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology (2005) 0.92
T₁ mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy. Circ Cardiovasc Imaging (2014) 0.91
Neurotoxicity in breast cancer survivors ≥10 years post-treatment is dependent on treatment type. Brain Imaging Behav (2015) 0.91
Early and presenting symptoms of dementia with lewy bodies. Dement Geriatr Cogn Disord (2011) 0.91
Preliminary evidence of hippocampal damage in chronic users of ecstasy. J Neurol Neurosurg Psychiatry (2011) 0.91
AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. Eur J Nucl Med Mol Imaging (2008) 0.91
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging (2013) 0.90
Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study. J Clin Psychiatry (2011) 0.90
Rigidity and bradykinesia reduce interlimb coordination in Parkinsonian gait. Arch Phys Med Rehabil (2005) 0.90
Continuous enriched environment improves learning and memory in adult NMRI mice through theta burst-related-LTP independent mechanisms but is not efficient in advanced aged animals. Mech Ageing Dev (2011) 0.89
Ecstasy in the brain: a model for neuroimaging. J Neuropsychiatry Clin Neurosci (2002) 0.89
No association between striatal dopamine transporter binding and body mass index: a multi-center European study in healthy volunteers. Neuroimage (2012) 0.89
Varenicline increases in vivo striatal dopamine D2/3 receptor binding: an ultra-high-resolution pinhole [123I]IBZM SPECT study in rats. Nucl Med Biol (2012) 0.88
Design, synthesis and in vitro evaluation of bridgehead fluoromethyl analogs of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) for the 5-HT(1A) receptor. Eur J Med Chem (2011) 0.88
Modulation of 5-HT7 receptor: effect on object recognition performances in mice. Psychopharmacology (Berl) (2013) 0.88
Neurotoxic effects of ecstasy on the thalamus. Br J Psychiatry (2008) 0.88
Diet-induced changes in the Lean Brain: Hypercaloric high-fat-high-sugar snacking decreases serotonin transporters in the human hypothalamic region. Mol Metab (2013) 0.88
Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.86
Comparison of the effects of erythropoietin and its carbamylated derivative on behaviour and hippocampal neurogenesis in mice. Neuropharmacology (2010) 0.86
Validity of [123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse (2002) 0.86
3D Pharmacophore, hierarchical methods, and 5-HT4 receptor binding data. J Enzyme Inhib Med Chem (2008) 0.86
Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease. Mov Disord (2014) 0.85